Prosecution Insights
Last updated: April 19, 2026

Janssen Pharmaceuticals Inc.

7 pending office actions

Portfolio Summary

7
Total Pending OAs
2
Final Rejections
5
Non-Final OAs

Pending Office Actions

App #TitleExaminerArt UnitStatusFiled
18858778 VIAL HOLDER CHEUNG, CHUN HOI 3736 Non-Final OA Oct 22, 2024
18571817 PROCESSES FOR THE PREPARATION OF (S)-2-(4-CHLORO-2-METHOXYPHENYL)-2-((3 -METHOXY-5-(M ETHYLSULFONYL)PHENYL)AMINO)-1 -(1H-INDOL-3-YL)ETHENONE DERIVATIVES PIHONAK, SARAH 1627 Non-Final OA Dec 19, 2023
18498448 COMPOSITIONS AND METHODS FOR ENHANCING GENE EXPRESSION GROOMS, TIFFANY NICOLE 1637 Final Rejection Oct 31, 2023
18035279 SOLID FORMULATION BAUER, BRIANNA LEE 1623 Non-Final OA May 03, 2023
17998592 STABILIZED CORONAVIRUS SPIKE PROTEIN FUSION PROTEINS WANG, RUIXUE 1672 Non-Final OA Nov 11, 2022
17806581 RECOMBINANT VIRUS REPLICON SYSTEMS AND USES THEREOF MARVICH, MARIA 1634 Final Rejection Jun 13, 2022
17763590 DRUG DELIVERY DEVICE INCORPORATING ELECTRICAL SYSTEM CONTAMINATION PROTECTION, POWER SOURCE MANAGEMENT, POWER SOURCE MONITORING, AND/OR POWER SOURCE OPERATION PATEL, ROHAN DEEP 3785 Non-Final OA Mar 24, 2022

Managing Janssen Pharmaceuticals Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month